Jupiter Neurosciences doses first patient in Phase 2a Parkinson's trial
Jupiter Neurosciences (NASDAQ: JUNS) has dosed the first patient in its Phase 2a RESET trial, evaluating JOTROL, the company's proprietary micellar formulation of trans-resveratrol, in people living with Parkinson's disease. The milestone marks the transition of the candidate from Phase 1 healthy-volunteer work into a patient population, and arrives alongside a disclosure that the company has engaged strategic adviser Tungsten Advisors to explore options including asset sales, licensing deals, partnerships and business combinations.
The dual announcement is a common signal from small-cap clinical-stage companies: progressing the science while simultaneously testing appetite among potential acquirers or licensees. Jupiter said its board has not approved any transaction and will not provide updates unless and until one is agreed.
The RESET study
RESET (RESvEraTrol in Parkinson's Disease) is a multicentre, randomised, double-blind, placebo-controlled trial expected to enrol approximately 30 patients. Participants are assigned 1:1:1 to one of two oral dose levels of JOTROL or placebo over a 12-week treatment period. Georgetown University is the study sponsor, with Fernando Pagan, professor of neurology and vice chairman of the department at Georgetown University School of Medicine, serving as principal investigator. Georgetown sub-investigator Charbel Moussa has disclosed financial interests in Jupiter.
Primary objectives cover safety, tolerability and pharmacokinetics, including plasma and cerebrospinal fluid exposure. Secondary and exploratory assessments will examine biomarkers linked to mitochondrial function, energy metabolism and neuroinflammation, as well as clinical outcome measures intended to inform the design of any subsequent, larger study.
JOTROL's rationale rests on the relatively poor oral bioavailability of conventional resveratrol. In a completed Phase 1 study in healthy volunteers, Jupiter reported that the micellar formulation produced increased systemic exposure and measurable resveratrol concentrations in cerebrospinal fluid, with no serious adverse events recorded. Preclinical work in a Parkinson's disease model also indicated neuroprotective effects, including improved motor function measures.
Market context and competitive landscape
Parkinson's disease represents a substantial and underserved therapeutic opportunity. Approximately 1.1 million people in the United States currently live with the condition, a figure the Parkinson's Foundation projects will reach 1.2 million by 2030. No disease-modifying therapy has yet been approved; all currently available treatments address symptoms rather than underlying neurodegeneration. The global Parkinson's drug market was valued at roughly $5.65 billion in 2024 and is forecast to reach approximately $7.58 billion by 2030, according to figures cited in the release.
Multiple companies are pursuing disease-modification in Parkinson's, with programmes targeting alpha-synuclein aggregation, GBA1 mutations, LRRK2 inhibition and mitochondrial pathways. JOTROL's mechanism sits in the mitochondrial and oxidative-stress space, an area that has attracted interest but has not yet yielded an approved agent. The 30-patient RESET study is modest in scale and is designed as an exploratory Phase 2a to generate biomarker and safety signals rather than to provide definitive efficacy evidence. Investors and potential partners will be watching closely for the pharmacodynamic biomarker data, which will form the clearest early indicator of whether JOTROL engages its intended biological targets in patients.
Chief executive Christer Rosén said the dosing of the first patient was "a significant milestone" representing "the culmination of years of scientific, regulatory and clinical development work." The company said it remains focused on efficient enrolment and will provide programme updates as data become available.